Tracers / [225Ac]Ac-FAPI-04
[225Ac]Ac-FAPI-04
Also written as FAPI-04; [Ac-225]Ac-FAPI-04
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- FAP inhibitor (FAPI)
- Target / mechanism
- Targets fibroblast activation protein (FAP) expressed on cancer-associated fibroblasts PMID 41599688
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/ga68-fapi04/">ga68-fapi04</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 41599688 2026 Pharmaceuticals (Basel) |
Need this precursor?We can point you to suppliers for [225Ac]Ac-FAPI-04, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Stage set/updated at stage 23 from PMID 41599688: 'α-emitting radiotracers (e.g., [225Ac]Ac-FAPI-04) demonstrate potent antitumor effects in preclinical models.'.